Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vitamin D Supplementation in Healthy Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01126671
Recruitment Status : Completed
First Posted : May 20, 2010
Results First Posted : April 19, 2013
Last Update Posted : June 4, 2018
Sponsor:
Information provided by (Responsible Party):
Sarah Pitts, Boston Children's Hospital

Brief Summary:
This double blind, randomized controlled trial compares two supplemental doses of vitamin D in health adolescents.

Condition or disease Intervention/treatment Phase
Vitamin D Supplementation Drug: Supplemental Vitamin D Not Applicable

Detailed Description:
Vitamin D deficiency is a common problem. Currently, data do not support a recommended vitamin D supplementation dose for health adolescents to maintain normal vitamin D levels. This double blind, randomized controlled 12 week trial compares the use of two supplemental doses of vitamin D in this population.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Clinical Trial of Vitamin D Supplementation in Healthy Adolescents
Study Start Date : November 2008
Actual Primary Completion Date : June 2011
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin D
Drug Information available for: Vitamin D

Arm Intervention/treatment
Active Comparator: Low Dose Vitamin D
Subjects are randomized to take 200 IU vitamin D3 daily in this arm.
Drug: Supplemental Vitamin D
Subjects were randomized to either take 200 IU of vitamin D or 1000 IU of vitamin D daily for 11 weeks and labs were compared before and after.

Active Comparator: High Dose Vitamin D
Subjects are randomized to take 1000 IU vitamin D3 daily in this arm.
Drug: Supplemental Vitamin D
Subjects were randomized to either take 200 IU of vitamin D or 1000 IU of vitamin D daily for 11 weeks and labs were compared before and after.




Primary Outcome Measures :
  1. Baseline 25 Hydroxy Vitamin D (25OHD) Levels [ Time Frame: Baseline ]
    25OHD will be drawn at baseline prior to starting vitamin D supplementation.

  2. Follow-up 25OHD Levels [ Time Frame: 12 weeks ]
    After 11weeks of treatment, repeat 25OHD levels will be drawn to assess subject response to vitamin D supplementation.


Secondary Outcome Measures :
  1. Baseline Assessment of Bone Markers [ Time Frame: Baseline ]
    Bone specific alkaline phosphatase, CTx, and osteocalcin will be assessed at baseline prior to subjects starting vitamin D supplementation

  2. Assessment of Bone Markers at Follow-up [ Time Frame: 12 weeks ]
    After 11 weeks of vitamin D supplementation bone specific alkaline phosphatase, osteocalcin, and CTx will be repeated to see response to therapy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   11 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 11-18 years old
  • healthy

Exclusion Criteria:

  • chronic disease
  • use of medication known to effect bone or vitamin D metabolism
  • abnormal vitamin D or calcium at screening
  • pregnant
  • body mass index <5% or >95%

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01126671


Locations
Layout table for location information
United States, Massachusetts
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Boston Children's Hospital
Investigators
Layout table for investigator information
Principal Investigator: Melissa Putman, MD Childrens Hospital, Boston
Principal Investigator: Sarah Pitts, MD Childrens Hospital, Boston
Publications:
Layout table for additonal information
Responsible Party: Sarah Pitts, Attending Physician, Boston Children's Hospital
ClinicalTrials.gov Identifier: NCT01126671    
Other Study ID Numbers: 08-06-0271
First Posted: May 20, 2010    Key Record Dates
Results First Posted: April 19, 2013
Last Update Posted: June 4, 2018
Last Verified: May 2018
Keywords provided by Sarah Pitts, Boston Children's Hospital:
vitamin D
Additional relevant MeSH terms:
Layout table for MeSH terms
Vitamin D
Vitamins
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents